RPRX
Royalty Pharma Plc
NASDAQ · Healthcare · Biotechnology · US
$67.30
−0.40%Year over year
Reported trailing growth
- Revenue
- +11.4%
- EBITDA
- -2.2%
- EBIT
- +2.1%
- EPS
- -21.9%
- Free cash flow
- +23.1%
- Operating cash flow
- +23.1%
Forward estimates
Based on analyst estimates
- Revenue
- +36.0%
- EBITDA
- +156.0%
- EPS
- +201.1%
Three-year CAGR
- Revenue
- +2.1%
- EBITDA
- +56.9%
- EBIT
- +71.9%
- Net income
- +162.1%
- EPS
- +187.7%
- Free cash flow
- +5.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026